Reagents and kits will lead neuro immunoassay sales through 2036 with 40.0% share of the product segment in 2026, driven by standardized treatment protocols and established clinical procurement patterns. The market is projected to reach USD 3.2 billion in 2026 and USD 6.38 billion by 2036, creating an incremental opportunity of USD 3.17 billion.